Four Children Experience HIV Remission: IMPAACT P1115 Results Published in The Lancet HIV

The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network is proud to announce the publication of results from P1115 in The Lancet HIV.  

P1115 is a Phase I/II, multi-center, proof-of-concept study that explores the effects of early intensive antiretroviral therapy on achieving HIV remission in neonates. The study also assesses the safety and pharmacokinetics of early intensive antiretroviral therapy in neonates. 

Building upon data first presented at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), the new publication reports four children remained free of detectable HIV for more than one year after their antiretroviral therapy was paused to see if they could achieve HIV remission. 

The IMPAACT Network congratulates and thanks the protocol team and study sites for their hard work on P1115 and publishing these important findings. We sincerely appreciate the ongoing commitment from the study participants and their families to make this study possible. We further acknowledge and thank the IMPAACT Community Advisory Board and the Community Advisory Boards at each site for their ongoing partnership and engagement. This milestone represents a significant step forward in pediatric HIV research.